HomeAI · summaries
Storia in 2 fonti
GSK, Hansoh ADC extends survival in lung cancer study
GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
GSK, Hansoh ADC extends survival in lung cancer study
GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers.
- ·
benzinga.com
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership - GSK (NYSE:GSK)
GSK-backed Ris-Rez posts positive Phase 3 survival data in small-cell lung cancer as the company moves to end its collaboration with Alector.